Devonian Health GroupDVHGF 49 PS Ratio is 8.48 as of Jul. 08, 2026, which is 4% above its 10-year median of 8.14. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 929 Biotechnology companies, Devonian Health Group ranks better than 61.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Devonian Health Group's share price is $7.00.
Devonian Health Group's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.83. Hence, Devonian Health Group's PS Ratio for today is 8.48.
The historical rank and industry rank for Devonian Health Group's PS Ratio or its related term are showing as below:
DVHGF'
s PS Ratio Range Over the Past 10 Years
Min: 0.5 Med: 8.14 Max: 2400
Current: 6.29
During the past 12 years, Devonian Health Group's highest PS Ratio was 2400.00. The lowest was 0.50. And the median was 8.14.
DVHGF's PS Ratio is ranked better than 61.03% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs DVHGF: 6.29
Devonian Health Group Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Devonian Health Group was -91.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 101.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 51.40% per year.
During the past 12 years, Devonian Health Group's highest 3-Year average Revenue per Share Growth Rate was 101.80% per year. The lowest was -31.20% per year. And the median was -16.40% per year.
Back to Basics: PS Ratio
Devonian Health Group (OTCPK:DVHGF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Devonian Health Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Devonian Health Group's Share Price of today is $7.00. Devonian Health Group's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Devonian Health Group (DVHGF) has a PS Ratio of 8.48 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Devonian Health Group and its competitors. This is near median its historical median of 8.14. Over the past decade, Devonian Health Group's PS Ratio has ranged from 0.50 to 2,400.00. According to the industry distribution chart, Devonian Health Group ranks #362 out of 929 companies in the Biotechnology industry, placing it in the top 39%.
Is Devonian Health Group's PS Ratio too high?
Devonian Health Group's current PS Ratio of 8.48 is near median its 10-year median of 8.14. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2,400.00. The Biotechnology industry median PS Ratio is 9.64. Devonian Health Group's value of 8.48 is 12% below this industry median. Based on the distribution chart, Devonian Health Group ranks #362 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #362 out of 929 companies for PS Ratio. This puts Devonian Health Group in the upper half of its industry. The industry median PS Ratio is 9.64. Devonian Health Group's value of 8.48 is 12% below this benchmark. Historically, Devonian Health Group's own PS Ratio has ranged from 0.50 to 2,400.00 over the past decade. While the company's 10-year median is 8.14 vs. the industry median of 9.64, Devonian Health Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current PS Ratio of 8.48 is 12% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current PS Ratio is 8.48, which is near median its own 10-year median of 8.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $7.00 — trading 224.1% above its estimated fair value. The current PS Ratio is 8.48, which is near median its 10-year median of 8.14 and 12% below the Biotechnology industry median of 9.64. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current PS Ratio is 8.48 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 224.1% above its estimated GF Value™ of $2.16.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
PS Ratio: 8.48 (near median its 10-year median of 8.14)
GF Value™: $2.16 vs. price of $7.00 (224.1% above fair value)
Industry Position: 12% below the Biotechnology median (#362 of 929)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
